Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
2013年6月6日 - 12:21AM
ビジネスワイヤ(英語)
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical
company that designs, develops, and markets a premium array of
topically-delivered therapeutic healthcare products, announced
today that Mr. Neil Mellor will join the company as Senior
Consultant, Chief Operations Officer. Mr. Mellor has over 25 years
of experience in the pharmaceutical industry, both in Canada and
Europe. The majority of Mr. Mellor’s background is in sales,
marketing and business development for companies such as Merck,
Pharmacia (now Pfizer), and Solvay Pharma (now Abbott
Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director
of Business Development at Solvay Pharma. In addition, Mr. Mellor
served as President of the Canadian Healthcare Licensing
Association (CHLA) from 2007 to 2008 and remains an active member
of the Board of the CHLA. Mr. Mellor is currently the President of
Global Health Link, a healthcare consulting company serving
Canadian and US clients. We are especially pleased to have such an
accomplished professional as Mr. Mellor on board to help with our
future plans for our products, beginning with our lead product
VIORRATM,” commented Mr. John Adams, of Easton Pharmaceuticals’.
"Mr. Mellor’s vast experience in marketing and licensing will help
us navigate the sometimes uncertain waters of the different markets
Easton Pharmaceuticals is considering, and will help us focus on
the design and execution of key business activities which will
enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company
that designs, develops, and markets a premium array of
topically-delivered therapeutic healthcare products, focused on
skin and circulatory conditions that impact a large and expanding
numbers of consumers including health issues related to male and
female sexual dysfunction, scar and stretch marks, cellulite and
varicose veins. The world market for these conditions is in excess
of US$10 billion.
The company's proprietary gel formulation is an innovative and
unique transdermal delivery system. Easton Pharmaceuticals’
flagship product, VIORRA, is an over-the-counter aid to help
restore and improve vaginal moisture and elasticity which plays an
important role in women’s sexual desire and arousal , FSAD (Female
Sexual Arousal Disorder). The world market for products which treat
this disorder is in excess of US$2 billion. VIORRA is a topical,
daily-use product classified by the US Food and Drug Administration
(FDA) as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com or
http://www.ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.Tel: +1(416)
619-0291Tel: +1(347) 284-0192Email and Media
Relations: info@lamindustries.comEmail and Media
Relations: info@ashleybiomedical.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 12 2024 まで 1 2025
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 1 2024 まで 1 2025